Keyphrases
Netherlands
100%
Economic Evaluation
100%
Influenza
100%
Influenza Complications
100%
Baloxavir Marboxil
100%
Cost-effectiveness Analysis
66%
Budget Impact Analysis
66%
Seasonal Influenza
66%
Epidemiological Situation
66%
Working Population
33%
Comorbidity
33%
High Risk
33%
Cost-effectiveness
33%
Dutch Population
33%
Societal Perspective
33%
Willingness-to-pay Threshold
33%
Treatment Options
33%
Cost-effective Treatment
33%
Productivity Gains
33%
Budget Impact
33%
Patients at Risk
33%
Influenza Epidemic
33%
Quality-adjusted Life Expectancy
33%
Duration of Illness
33%
Influenza Vaccine
33%
Vaccine Effectiveness
33%
Baloxavir
33%
Decision Tree Model
33%
Medicine and Dentistry
Cost-Effectiveness Analysis
100%
Base
100%
Quality Adjusted Life Year
100%
Seasonal Influenza
100%
Baloxavir Marboxil
100%
Antivirus Agent
100%
Health Care Cost
66%
Disease
33%
Life Expectancy
33%
Lifespan
33%
Baloxavir
33%
Comorbidity
33%
Pharmacology, Toxicology and Pharmaceutical Science
Base
100%
Seasonal Influenza
100%
Antivirus Agent
100%
Baloxavir Marboxil
100%
Disease
33%
Life Expectancy
33%
Baloxavir
33%
Comorbidity
33%
Immunology and Microbiology
Influenza
100%
Quality Adjusted Life Year
37%
Lifespan
12%
Life Expectancy
12%
Decision Trees
12%
Comorbidity
12%